Greenwich LifeSciences, Inc. (GLSI)

NASDAQ: GLSI · IEX Real-Time Price · USD
20.24
0.25 (1.25%)
At close: Jan 14, 2022 4:00 PM
20.50
0.26 (1.28%)
After-hours:Jan 14, 2022 4:30 PM EST
Market Cap265.62M
Revenue (ttm)n/a
Net Income (ttm)-3.36M
Shares Out13.12M
EPS (ttm)-0.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume53,908
Open20.50
Previous Close19.99
Day's Range19.22 - 20.61
52-Week Range19.22 - 69.77
Betan/a
AnalystsBuy
Price Target76.50 (+278.0%)
Earnings Daten/a

About GLSI

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Staffo...

IndustryBiotechnology
IPO DateSep 25, 2020
Employees1
Stock ExchangeNASDAQ
Ticker SymbolGLSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for GLSI stock is "Buy" and the 12-month stock price forecast is 76.50.

Price Target
$76.50
(277.96% upside)
Analyst Consensus: Buy

News

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

1 month ago - Business Wire

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low ...

1 month ago - Benzinga

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential Fo...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

1 month ago - Business Wire

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

1 month ago - Business Wire

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upc...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

1 month ago - Business Wire

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

1 month ago - Business Wire

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

1 month ago - Business Wire

Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

1 month ago - Business Wire

Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

2 months ago - Business Wire

Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

2 months ago - Business Wire

Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts

2 months ago - Business Wire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - October 20, 2021) -  Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fid...

2 months ago - Newsfile Corp

The Moonshot Investor: The Insider Track Strategy

Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung's Moonshot Investor series. Investors interested in finding stocks with 100x potential or more can subs...

Other symbols:BMEAVOLT
3 months ago - InvestorPlace

A Controversial Moonshot Stock Just Got a Lot More Interesting

Studies have found that insiders outperform the market by 6-15%. Over a long period, that's an incredible achievement and worth understanding.

3 months ago - InvestorPlace

Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston

3 months ago - Business Wire

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

3 months ago - Business Wire

Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

4 months ago - Business Wire

Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

4 months ago - Business Wire

Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference

4 months ago - Business Wire

Greenwich LifeSciences Set to Join Russell 2000® Index

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Set to Join Russell 2000® Index

7 months ago - Business Wire

Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer ...

Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were pre...

7 months ago - Benzinga

Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming th...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming GP2 Treatment is Well Tolerated

7 months ago - Business Wire

1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?

The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?

8 months ago - The Motley Fool

Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commerc...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization

8 months ago - Business Wire

Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

9 months ago - Business Wire